fetaLife Technologies, a partner of Catalonia.health, has won the 2026 eAwards Spain with a liquid incubator designed to recreate the uterine environment and support the survival and development of extremely premature babies. This award adds to its recognition as the best deep tech start-up at the 2026 Barcelona Deep Tech Summit.
The NTT DATA Foundation celebrated its 25th anniversary under the slogan “The Future Continues” at a gala held at the Real Casino de Madrid on 5 November. Since its creation in 2001, the foundation has supported more than 13,000 entrepreneurs and brought technology to over 32,000 children and young people across 15 countries in Europe and Latin America.
One of the highlights of the celebration was the announcement of fetaLife Technologies as the winner of the 2026 eAwards Spain, which recognise technology-driven entrepreneurial projects with the potential to make a social impact. In addition to the financial prize, the award will allow fetaLife to represent Spain at the international eAwards final, where it will compete for a €100,000 prize and specialised mentoring to help advance its project.
Best deep tech start-up at the 2026 Barcelona Deep Tech Summit
fetaLife Technologies has also received the award for Best Deep Tech Start-up at the 2026 Barcelona Deep Tech Summit. fetaLife Technologies is a spin-off of the University of Barcelona, Hospital Clínic Barcelona and SJD Barcelona Children’s Hospital, established in 2025.
The company is developing a liquid incubator, or artificial placenta, for extremely premature babies born between 22 and 26 weeks of gestation. This technology aims to replicate the conditions of the womb to support babies’ development during a particularly critical stage. The project, which emerged from fetal and neonatal medicine research at BCNatal, aims to advance a new therapeutic alternative that could improve survival rates and reduce complications associated with extreme prematurity.
The company is currently raising €6 million to continue developing the technology and move towards its first clinical trials in humans, planned for 2029.
At Catalonia.health, we congratulate the entire fetaLife Technologies team on these two achievements, which highlight the potential of technological innovation to address major challenges in healthcare.
© Catalonia.health, 2026
Comments